BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Telbisz Á, Ambrus C, Mózner O, Szabó E, Várady G, Bakos É, Sarkadi B, Özvegy-Laczka C. Interactions of Potential Anti-COVID-19 Compounds with Multispecific ABC and OATP Drug Transporters. Pharmaceutics 2021;13:81. [PMID: 33435273 DOI: 10.3390/pharmaceutics13010081] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Siripongboonsitti T, Ungtrakul T, Watanapokasin N, Timsri P, Wongpakdee K, Wattanasin P, Pavitrapok C, Khunvichai A, Jamnongtanachot P, Mueannoom W, Kitpoka T, Arjharn W, Mahanonda N. Pharmacokinetic Comparison of Favipiravir Oral Solution and Tablet Formulations in Healthy Thai Volunteers. Clin Pharmacol Drug Dev 2023;12:14-20. [PMID: 35877195 DOI: 10.1002/cpdd.1149] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Assad M, Parveen Z, Farman S, Khurshid B, Hashmi MA, Khan KM, Khurshid A. In Vitro Screening and MD Simulations of Thiourea Derivatives against SARS-CoV-2 in Association with Multidrug Resistance ABCB1 Transporter. ACS Omega 2022;7:47671-9. [PMID: 36569212 DOI: 10.1021/acsomega.2c04671] [Reference Citation Analysis]
3 Moreno S, Fickl M, Bauer I, Brunner M, Rázková A, Rieder D, Delazer I, Micura R, Lusser A. 6-Thioguanosine Monophosphate Prodrugs Display Enhanced Performance against Thiopurine-Resistant Leukemia and Breast Cancer Cells. J Med Chem 2022. [DOI: 10.1021/acs.jmedchem.2c01010] [Reference Citation Analysis]
4 Lee J, Kim J, Kang J, Lee HJ. COVID-19 drugs: potential interaction with ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein. J Pharm Investig 2022. [DOI: 10.1007/s40005-022-00596-6] [Reference Citation Analysis]
5 Charitou T, Kontou PI, Tamposis IA, Pavlopoulos GA, Braliou GG, Bagos PG. Drug genetic associations with COVID-19 manifestations: a data mining and network biology approach. Pharmacogenomics J 2022. [DOI: 10.1038/s41397-022-00289-1] [Reference Citation Analysis]
6 Corritori S, Savchuk N, Pauza CD. Risk/Benefit Profiles of Currently Approved Oral Antivirals for Treatment of COVID-19: Similarities and Differences. COVID 2022;2:1057-1076. [DOI: 10.3390/covid2080078] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Stefan SM, Jansson PJ, Pahnke J, Namasivayam V. A curated binary pattern multitarget dataset of focused ATP-binding cassette transporter inhibitors. Sci Data 2022;9:446. [PMID: 35882865 DOI: 10.1038/s41597-022-01506-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Stetkevich SA, Anzelc MJ, Burkhart CG. Intranasal Ivermectin Spray, the Sunscreen to COVID-19. TODJ 2022;16. [DOI: 10.2174/18743722-v16-e2205190] [Reference Citation Analysis]
9 Merches K, Breunig L, Fender J, Brand T, Bätz V, Idel S, Kollipara L, Reinders Y, Sickmann A, Mally A, Lorenz K. The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro. Arch Toxicol 2022. [PMID: 35579693 DOI: 10.1007/s00204-022-03306-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Biswas M, Sawajan N, Rungrotmongkol T, Sanachai K, Ershadian M, Sukasem C. Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies. Front Pharmacol 2022;13:835136. [DOI: 10.3389/fphar.2022.835136] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
11 Namasivayam V, Stefan K, Pahnke J, Stefan SM. Binding mode analysis of ABCA7 for the prediction of novel Alzheimer's disease therapeutics. Comput Struct Biotechnol J 2021;19:6490-504. [PMID: 34976306 DOI: 10.1016/j.csbj.2021.11.035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Covantev S, Volkov SI, Samsonova KI. Alternative Management of Cushing's Syndrome During Covid-19 Pandemic. COVID 2022;3. [DOI: 10.2174/2666796702666210913095645] [Reference Citation Analysis]
13 Moreno S, Brunner M, Delazer I, Rieder D, Lusser A, Micura R. Synthesis of 4-thiouridines with prodrug functionalization for RNA metabolic labeling. RSC Chem Biol . [DOI: 10.1039/d2cb00001f] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Namasivayam V, Stefan K, Silbermann K, Pahnke J, Wiese M, Stefan SM. Structural feature-driven pattern analysis for multitarget modulator landscapes. Bioinformatics 2022;38:1385-92. [PMID: 34888617 DOI: 10.1093/bioinformatics/btab832] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Montanha MC, Fabrega F, Howarth A, Cottura N, Kinvig H, Bunglawala F, Lloyd A, Denti P, Waitt C, Siccardi M. Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling. Clin Pharmacokinet 2021. [PMID: 34635995 DOI: 10.1007/s40262-021-01067-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Miller SR, McGrath ME, Zorn KM, Ekins S, Wright SH, Cherrington NJ. Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites. Mol Pharmacol 2021;100:548-57. [PMID: 34503974 DOI: 10.1124/molpharm.121.000333] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
17 Ambrus C, Bakos É, Sarkadi B, Özvegy-Laczka C, Telbisz Á. Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics. Sci Rep 2021;11:17810. [PMID: 34497279 DOI: 10.1038/s41598-021-97160-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
18 Ungvári O, Király L, Bakos É, Özvegy-Laczka C. 8-acetoxy-trisulfopyrene as the first activatable fluorogenic probe for add-and-read assessment of Organic anion-transporting polypeptides, OATP1B1, OATP1B3, and OATP2B1. FASEB J 2021;35:e21863. [PMID: 34411334 DOI: 10.1096/fj.202100648R] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Namasivayam V, Silbermann K, Pahnke J, Wiese M, Stefan SM. Scaffold fragmentation and substructure hopping reveal potential, robustness, and limits of computer-aided pattern analysis (C@PA). Comput Struct Biotechnol J 2021;19:3269-83. [PMID: 34141145 DOI: 10.1016/j.csbj.2021.05.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
20 Villoutreix BO, Krishnamoorthy R, Tamouza R, Leboyer M, Beaune P. Chemoinformatic Analysis of Psychotropic and Antihistaminic Drugs in the Light of Experimental Anti-SARS-CoV-2 Activities. Adv Appl Bioinform Chem 2021;14:71-85. [PMID: 33880039 DOI: 10.2147/AABC.S304649] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
21 Rendic SP. Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects. Arch Toxicol 2021;95:1535-46. [PMID: 33719007 DOI: 10.1007/s00204-021-03025-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
22 Nies AT, König J, Hofmann U, Kölz C, Fromm MF, Schwab M. Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters. Pharmaceutics 2021;13:369. [PMID: 33802215 DOI: 10.3390/pharmaceutics13030369] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
23 Pott-Junior H, Paoliello MMB, Miguel AQC, da Cunha AF, de Melo Freire CC, Neves FF, da Silva de Avó LR, Roscani MG, Dos Santos SS, Chachá SGF. Use of ivermectin in the treatment of Covid-19: A pilot trial. Toxicol Rep 2021;8:505-10. [PMID: 33723507 DOI: 10.1016/j.toxrep.2021.03.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 13.5] [Reference Citation Analysis]
24 Fricke-Galindo I, Falfán-Valencia R. Pharmacogenetics Approach for the Improvement of COVID-19 Treatment. Viruses 2021;13:413. [PMID: 33807592 DOI: 10.3390/v13030413] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]